BBNX: Revenue grew 30%, but losses widened as Mint may defer Q4 sales

What happened

Third-quarter revenue rose 30% from a year earlier to $35.5 million, led by 118% growth in PBP, while net and adjusted EBITDA losses widened. Full-year 2026 revenue guidance increased, but prospective Mint users could defer up to $8.5 million of fourth-quarter sales.

Confirmed

Global impact / market context

Faster revenue growth alongside wider losses means the company is spending heavily to expand. If up to $8.5 million of fourth-quarter sales slip because Mint users wait, reported revenue could come in lower than otherwise expected, which may unsettle investors focused on growth.

Analyst inference

Investors often weigh revenue growth against losses when judging a growing medical device company. The raised 2026 revenue guidance signals expected demand, but the possible Mint-related sales deferral introduces timing uncertainty, so the fourth-quarter sales figure may matter more than usual.

Analyst inference

What to watch

1. Whether the prospective Mint users who could defer up to $8.5 million of fourth-quarter sales actually delay those purchases, and how much of that amount shifts into later periods. Confirmed
2. The company could give more detail on when deferred Mint sales might be recognized, which would help investors judge whether the shift is a timing issue or weaker demand. Proposed
3. Watch whether spending that widened net and adjusted EBITDA losses continues at the same pace, since sustained costs could keep losses wide even as revenue grows. Analyst inference

Evidence

• Original source link unavailable